Free Trial

MDxHealth (NASDAQ:MDXH) Updates Q2 2025 Earnings Guidance

MDxHealth logo with Medical background

Key Points

  • MDxHealth updated its Q2 2025 earnings guidance to an earnings per share of -0.150, compared to the consensus estimate of -0.117, and provided revenue guidance of $26.6 million, slightly below the consensus estimate of $26.9 million.
  • Shares of MDxHealth increased by 0.8% during midday trading, reaching a price of $2.49, with a reported market cap of $117.75 million.
  • Analysts have mixed ratings for MDxHealth, with Craig Hallum giving it a "buy" rating and a target price of $8.00, while Wall Street Zen upgraded it to a "hold" rating.
  • Interested in MDxHealth? Here are five stocks we like better.

MDxHealth (NASDAQ:MDXH - Get Free Report) updated its second quarter 2025 earnings guidance on Tuesday. The company provided earnings per share guidance of -0.150--0.150 for the period, compared to the consensus earnings per share estimate of -0.117. The company issued revenue guidance of $26.6 million-$26.6 million, compared to the consensus revenue estimate of $26.9 million.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on MDXH shares. Craig Hallum started coverage on MDxHealth in a report on Thursday, July 17th. They set a "buy" rating and a $8.00 target price for the company. Wall Street Zen upgraded MDxHealth to a "hold" rating in a report on Saturday, May 24th.

Check Out Our Latest Research Report on MDXH

MDxHealth Trading Up 0.8%

Shares of MDxHealth stock traded up $0.02 during midday trading on Tuesday, reaching $2.49. 115,605 shares of the company's stock traded hands, compared to its average volume of 81,020. The company has a debt-to-equity ratio of 13.81, a quick ratio of 1.92 and a current ratio of 2.00. The company has a market cap of $117.75 million, a PE ratio of -2.17 and a beta of 1.41. The stock has a 50 day moving average of $2.22 and a 200-day moving average of $1.90. MDxHealth has a 12 month low of $1.35 and a 12 month high of $3.50.

MDxHealth (NASDAQ:MDXH - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.06). MDxHealth had a negative return on equity of 492.11% and a negative net margin of 41.02%. The firm had revenue of $24.29 million during the quarter, compared to analysts' expectations of $22.62 million. As a group, equities analysts expect that MDxHealth will post -1.15 EPS for the current fiscal year.

About MDxHealth

(Get Free Report)

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.

Recommended Stories

Earnings History and Estimates for MDxHealth (NASDAQ:MDXH)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in MDxHealth Right Now?

Before you consider MDxHealth, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MDxHealth wasn't on the list.

While MDxHealth currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Overlooked AI Stocks That Chipmakers Can’t Live Without
Palantir & AMD Earnings: Massive Options Setups Ahead
3 Value Plays Set to Explode

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines